Signed in as:
Signed in as:
Dry eye disease is a common condition that affects the eye and causes symptoms including irritation, dryness, and blurred vision. Progression of dry eye can be evaluated by observation of the cornea by corneal fluorescence staining and tear volume measurement using the phenol red thread test.
1.Rat model of Dry eye disease by surgical excision of ELG
In the rat model of dry eye disease by surgical excision of the extraorbitallachrymal gland (ELG), removal of the lacrimal gland severely limits tear secretion and induces symptoms of dry eye disease.
2.Mouse model of dry eye by scopolamine and desiccating condition
In this model, dry eye disease is induced by repeated injection with scopolamine. Dry eye stress is further induced by exposure to continuous airflow in a low-humidity environment.
Age-related Macular Degeneration (AMD) is a medical condition which may result in blurred or loss of vision in the center of the visual field due to damage to the macula of the retina and is one of the leading causes of vision loss and blindness in people over 50 years of age in developed countries. There are two forms of AMD; dry and wet AMD.
Naason Science offers a mouse model of dry AMD induced by NaIO3 injection. This model provides rapid phenotypic changes such as damage of tight junction integrity and thinning of retinal layers that can be assessed by immunohistochemical analyses.
Dry AMD can progress to wet AMD when abnormal blood vessels develop underneath the retina. Wet AMD can be induced by photocoagulation of the retina using the 532 nm laser. The choroidal neovascularization (CNV) formed by the laser can be measured in vivo using optical coherence tomography and fluorescein angiography. We also offer immunohistochemical analyses on flatmounts using markers for CNV and subretinal fibrosis, which often accompanies wet AMD.
In this Model, the 532 nm laser is applied in two stages in the same lesion to produce a more severe phenotype of AMD and to induce subretinal fibrosis. Fibrosis is quantified by immunohistochemical staining after flatmounting. In this Model, the area of fibrosis increases 30 days after the second laser burn, providing a platform to test therapeutic efficacy of compounds.